narcolepsy jnj Pages on BioPortfolio:

Results from other life science and pharmaceutical sites:

Pharmacological characterization of JNJ-28583867, ...[Eur J ...
After subcutaneous administration, JNJ-28583867 occupied both the histamine ... to treat excessive sleepiness caused by narcolepsy (a condition that causes ...
http://www.ncbi.nlm.nih.gov/pubmed/17765221...

Associated Professional Sleep Societies – SLEEP 2006 20th ...
RWJ-662733 (JNJ-1018457). The effects of this compound on. narcoleptic animals are reviewed in this report. Studies with ramelteon ...
http://www.biomedcentral.com/content/pdf/cd-686149.pdf...

Histamine H3 receptor antagonists: from target ide...[Biochem ...
Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 ... used to treat excessive sleepiness caused by narcolepsy (a condition that causes ...
http://www.ncbi.nlm.nih.gov/pubmed/17129577...

cd-881101 Paper alert Paper alert Antoniu SA Daneshtalab M ...
Pharmacological characterization of JNJ-28583867, a histamine H3 receptor antagonist and ... may represent an improved treatment modality for narcolepsy.
...
http://www.biomedcentral.com/content/download/xml/cd-881101....

British Journal of Pharmacology - The histamine H3 receptor: an ...
... with narcolepsy (www.clinicaltrials.gov). A recent publication described the pharmacology of a new class of compounds exemplified by JNJ-28583867, ...
http://www.nature.com/bjp/journal/v154/n6/full/bjp2008147a.h...

Paper alert
researchers suggest that a compound such as JNJ-28583867. would be clinically beneficial, ... modality for narcolepsy. As no control data were included ...
http://www.biomedcentral.com/content/pdf/cd-881101.pdf...

The histamine H: 3: receptor: from gene cloning to H: 3: receptor ...
The potent lead compound JNJ-5207852 (compound 28) (pKi = 9.5, .... a novel wakefulness-promoting drug for the treatment of narcolepsy has recently been ...
http://www.nature.com/nrd/journal/v4/n2/full/nrd1631.html...

cd-813461 Patent alert Patent alert Thomson Current Awareness ...
Johnson & Johnson is investigating a series of H3 antagonists for the treatment of narcolepsy and cognitive disorders. In February 2007, JNJ-17216478 was ...
http://www.biomedcentral.com/content/download/xml/cd-813461....

BioSpace offers Pharmaceutical, Biotechnology and Healthcare ...
21 Jun 2007 ... Development And Sales Of Narcolepsy Drug Modafinil 4/5/2006 More. .... Johnson & Johnson (JNJ) Sees 10 To 13 New Drugs Approved By 2007 ...
http://www.biospace.com/news_by_disease_results.aspx?TheRxId...

cd-893164 Paper alert Paper alert Antoniu SA Daneshtalab M ...
JNJ-26076713 is an V integrin antagonist that is effective in animal models of ... of orexinergic neurons in mice results in acquired murine narcolepsy, ...
http://www.biomedcentral.com/content/download/xml/cd-893164....

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright 1997-2008 - BioPortfolio Limited.